LONDON (Reuters) - Barriers to understanding pain are starting to fall and scientists and drug firms say a fresh approach is producing potential new drugs to hit where it hurts. Millions of people across the world suffer chronic pain -- such as nerve, joint or muscle pain that lasts weeks, months or years -- and many fail to get adequate relief, partly because ...

LONDON (Reuters) - It's been a bad month for Pfizer's <PFE.N> research labs but its head of R&D says the world's biggest drugmaker is on track to hit earlier targets for new drug filings despite the setbacks. "We have had some disappointments, there is no getting away from it," Martin Mackay told Reuters ...

FRANKFURT (Reuters) - Israel's Teva <TEVA.TA> has won the battle for German generic drugmaker Ratiopharm, paying an enterprise value of 3.625 billion euros to fix the industry leader's weakness in the world's second-largest generics market. Teva, which beat U.S. drugs powerhouse Pfizer <PFE.N> and Iceland's Actavis in the race ...

FRANKFURT/COLOGNE (Reuters) - The tussle over German generic drugs maker Ratiopharm is drawing to a close as the three remaining contenders square off in the final round of bidding, sources close to the deal told Reuters on Wednesday. Pfizer <PFE.N> will submit its bid on Wednesday, a person briefed on the matter said. Rival bidder Actavis of ...